Online citations, reference lists, and bibliographies.
← Back to Search

A Multicenter Phase II Study Of Cisplatin, Pemetrexed, And Bevacizumab In Patients With Advanced Malignant Mesothelioma.

J. Dowell, F. Dunphy, R. Taub, D. Gerber, Likheng Ngov, J. Yan, Y. Xie, H. Kindler
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
INTRODUCTION Malignant mesothelioma (MM) cells express the vascular endothelial growth factor (VEGF) receptor, and VEGF protein expression is detected in a majority of human mesothelioma biopsy specimens. Bevacizumab is a recombinant humanized monoclonal antibody that blocks the binding of VEGF to its receptor. We evaluated the addition of bevacizumab to cisplatin and pemetrexed as first-line treatment in patients with advanced, unresectable MM. METHODS Previously untreated MM patients with advanced, unresectable disease received cisplatin (75 mg/m(2)), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg) intravenously every 21 days for a maximum of 6 cycles. Patients with responsive or stable disease received bevacizumab (15 mg/kg) intravenously every 21 days until progression or intolerance. The primary endpoint was progression-free survival rate at 6 months. RESULTS 53 patients were enrolled at 4 centers; 52 were evaluable for this analysis. The progression-free survival rate at 6 months was 56% and the median progression-free survival was 6.9 months (95% confidence interval [CI], 5.3-7.8 months). The partial response rate was 40% and 35% of patients had stable disease. Median overall survival was 14.8 months (95% CI; 10.0-17.0 months). Grade 3/4 toxicities included neutropenia in 11%, hypertension in 6%, and venous thromboembolism in 13% of patients. CONCLUSION This trial evaluating the addition of bevacizumab to cisplatin and pemetrexed in patients with previously untreated, advanced MM failed to meet the primary endpoint of a 33% improvement in the progression-free survival rate at 6 months compared with historical controls treated with cisplatin and pemetrexed alone.
This paper references
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1001/jama.2011.51
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
V. Ranpura (2011)
10.1016/S0169-5002(03)91684-9
O-26 Thalidomide alone or in combination with cisplatin/Gemcitabine in malignant pleural mesothelioma (MM); Interim results from two parallel non randomized phase II studies
N. Pavlakis (2003)
10.1093/JNCI/DJM086
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
F. Scappaticci (2007)
10.1200/JCO.2011.29.15_SUPPL.7006
A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy.
P. Baas (2011)
10.1097/JTO.0b013e318229586e
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
L. Garland (2011)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
SU 5416 in malignant mesothelioma : a University of Chicago phase II consortium study
HL Kindler (2001)
10.1001/jama.2008.656
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
S. R. Nalluri (2008)
10.1002/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D
EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA
S. Kumar-Singh (1997)
10.1016/j.lungcan.2011.11.014
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
T. Jahan (2012)
10.1016/J.LUNGCAN.2004.10.005
Thalidomide in patients with malignant pleural mesothelioma.
P. Baas (2005)
10.1200/JCO.2002.10.088
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.
H. Dvorak (2002)
10.1200/JCO.2010.28.15_SUPPL.4609
Bevacizumab (BEV) and the risk of arterial thromboembolic events (ATE) in patients with renal cell carcinoma and other cancers: A large comprehensive meta-analysis of more than 13,000 patients.
G. Azzi (2010)
10.1002/ijc.10996
Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF‐C autocrine loops
R. Masood (2003)
10.1007/s004280050388
Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma
J. König (1999)
10.1111/j.1651-2227.1964.tb05158.x
Statistical Methods
G. W. Snedecor (1964)
10.1097/JTO.0b013e3182333df5
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group
S. Laurie (2011)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1200/JCO.2007.25.18_SUPPL.7526
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
T. Karrison (2007)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1046/j.1365-2559.2001.01211.x
Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1
Y. Soini (2001)
Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first - line therapy in patients with malignant pleural mesothelioma ( MPM )
GL Ceresoli (2011)
10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression
S. Kumar-Singh (1999)
10.1054/bjoc.2001.1997
Angiogenesis is an independent prognostic factor in malignant mesothelioma
J. Edwards (2001)
10.1016/S0084-3873(11)00193-3
Treatment-Related Mortality With Bevacizumab in Cancer Patients: A Meta-analysis
J. Thigpen (2011)
10.3109/02841860903524396
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
Vishal Ranpura (2010)
10.2307/2987141
Statistical methods
G. W. Snedecor (1980)
10.1200/JCO.2010.32.3220
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
H. Hurwitz (2011)
10.1002/path.824
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
10.1097/JTO.0b013e3181ec18db
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)



This paper is referenced by
The Immunogenic Effect of Local Radiation Therapy in a Murine Model of Mesothelioma
de la Maza Borja (2015)
10.3390/ijms18112293
The Effect of Aquaporin 1-Inhibition on Vasculogenic Mimicry in Malignant Mesothelioma
E. Pulford (2017)
10.5772/55722
Malignant Pleural Mesothelioma and the Role of Non– Operative Therapies
K. Lau (2013)
The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
C. C. Boons (2013)
10.1158/0008-5472.CAN-15-1796
Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.
Yusuke Takayama (2016)
10.1016/S1470-2045(18)30100-1
Novel therapies for malignant pleural mesothelioma.
A. Scherpereel (2018)
10.1016/j.jare.2014.11.012
Mesothelioma treatment: Are we on target? A review
B. Hiddinga (2015)
10.1016/j.cytogfr.2017.07.003
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.
L. Calabrò (2017)
Nintedanib : new treatment for malignant pleural mesothelioma
(2017)
10.1080/13543784.2019.1638363
What can independent research for mesothelioma achieve to treat this orphan disease?
A. Guazzelli (2019)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
10.1007/s12094-015-1464-y
Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases
D. Márquez-Medina (2015)
10.1186/s12885-018-5146-3
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
Y. Tsutani (2018)
HMGB-1 Release and the CD8+ T Cell Response Elicited by Radiation Treatment in Malignant Pleural Mesothelioma
M. Wu (2015)
10.1159/000368050
Naftopidil Is Useful for the Treatment of Malignant Pleural Mesothelioma
K. Mikami (2014)
10.1053/j.seminoncol.2019.06.001
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
A. Tsao (2019)
10.1016/j.pneumo.2012.12.003
Prise en charge diagnostique et thérapeutique du mésothéliome pleural malin
J. Delourme (2013)
10.2147/OTT.S113598
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
Pavel A. Levin (2017)
10.3892/or.2015.4058
Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model.
S. Kubo (2015)
10.2217/LMT.15.32
New directions in mesothelioma treatment
Anna K. Nowak (2015)
10.1093/ejcts/ezaa158
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
10.1080/14737140.2016.1244008
Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma
P. L. Chia (2016)
10.4172/1948-5956.1000285
Current Therapies for Malignant Mesothelioma
A. Shukla (2014)
10.1177/2373997515600403
Molecular-Targeted Therapy For Malignant Mesothelioma
Y. Tada (2015)
10.5772/55292
Mesothelioma: An Evidence-Based Review
J. Goudreault (2013)
10.1186/s40064-015-1123-3
A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene
Y. Tada (2015)
10.1016/j.ctrv.2012.12.005
Malignant mesothelioma: new insights into a rare disease.
J. Remon (2013)
10.1183/13993003.00953-2019
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
10.2147/LCTT.S83338
Modern management of malignant pleural mesothelioma
S. Patel (2016)
10.1634/theoncologist.2014-0122
Current issues in malignant pleural mesothelioma evaluation and management.
J. Ai (2014)
10.3389/fonc.2020.588563
The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis
O. Lauk (2020)
10.1159/000464410
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma
M. Mencoboni (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar